Tag: Medicare Part D
The potential for full Food and Drug Administration approval of the new Biogen-Esai Alzheimer’s drug (Leqembi) means that Medicare may make the drug available to beneficiaries. The $26,500 annual price tag associated with Leqembi will wreak havoc with Medicare finances, raise part B premiums, and place an enormous financial burden on afflicted families through the required copays. T…
President Biden, in his State of the Union speech, proposed giving Medicare the ability to negotiate lower prices for prescription drugs. I’m assuming the President means not only over-the-counter drugs covered under Part D but also medications administered in a doctor’s office covered under Part B. Medicare sorely needs that ability. While Medicare’s decision to…
